PHARMAC decision-making on new medicines. A case study
Peter Davis 1 *
+ Author Affiliations
- Author Affiliations
1 Emeritus Professor in Population Health and Social Science, University of Auckland, New Zealand.
* Correspondence to: pb.davis@auckland.ac.nz
Journal of Primary Health Care 14(1) 4-5 https://doi.org/10.1071/HCv14n1_ED2
Published: 13 April 2022
© 2022 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of The Royal New Zealand College of General Practitioners. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)
References
[1] PHARMAC. Te Pātaka Whaioranga. Annual Report for the year ended 30 June 2021. Wellington: New Zealand Government; 2021. Available at https://pharmac.govt.nz/assets/Annual-Report-2020-2021.pdf [Accessed 10 February 2022][2] Davis P. “Tough but fair”? The active management of the New Zealand drug benefits scheme by an independent Crown agency. Aust Health Rev 2004; 28 171–181.
| “Tough but fair”? The active management of the New Zealand drug benefits scheme by an independent Crown agency.Crossref | GoogleScholarGoogle Scholar |
[3] Morgan S, Hanley G, McMahon M, Barer M. Influencing drug prices through formulary-based policies: lessons from New Zealand. Healthcare Policy 2007; 3 1–18. Available at https://people.stfx.ca/blynch/Consortium%201%20dec%202007/Policy_vol3_no1_morgan.pdf
[4] Sarkisova F, Lessing C, Stretton C. Decision-making on listing new medicines for public funding in New Zealand: the case of ‘new’ type 2 diabetes medications. J Prim Health Care 2022; 14 13–20.
[5] Medicines New Zealand. A decade of modern medicines: an international comparison 2011-2020. IQVIA Report. 2021. https://www.medicinesnz.co.nz/fileadmin/user_upload/IQVIA_Report_-_A_Decade_of_Modern_Medicines_An_International_Comparison_2011-2020__FINAL_.pdf [Accessed 10 February 2022]
[6] Sarfati S, Jackson C, Macfarlane S, et al. Editorial. Cancer care at a crossroads: time to make a choice. NZ Med J 2019; 132 6–11.
[7] Evans J, Laking G, Strother M, et al. Mind the gap: an analysis of foregone health gains from unfunded cancer medicines in New Zealand. Semin Oncol 2016; 43 625–637.
| Mind the gap: an analysis of foregone health gains from unfunded cancer medicines in New Zealand.Crossref | GoogleScholarGoogle Scholar |
[8] Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ 2020; 371 m3434
| Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.Crossref | GoogleScholarGoogle Scholar |
[9] Pharmac Review Panel. Pharmac Review: Interim Report. Wellington, NZ: Ministry of Health; 2021. Available at https://pharmacreview.health.govt.nz/assets/Pharmac-Review-Interim-report.pdf [Accessed 10 February 2022]
